Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
| Regel 9: | Regel 9: | ||
| bgcolor="#cccccc" | | | bgcolor="#cccccc" | | ||
| - | '''Wetenschappelijk''' | + | '''Wetenschappelijk''' |
'''onderzoek''' | '''onderzoek''' | ||
| Regel 146: | Regel 146: | ||
| | | | ||
|- | |- | ||
| - | | | + | | Jet Gisolf |
| + | | Roche | ||
| | | | ||
| | | | ||
| + | | align="center" | x | ||
| | | | ||
| + | |- | ||
| | | | ||
| + | | Merck | ||
| + | | | ||
| + | | | ||
| + | | align="center" | x | ||
| + | | | ||
| + | |- | ||
| + | | | ||
| + | | Gilead | ||
| + | | | ||
| + | | | ||
| + | | align="center" | x | ||
| + | | | ||
| + | |- | ||
| + | | | ||
| + | | Shering Plough | ||
| + | | | ||
| + | | | ||
| + | | align="center" | x | ||
| + | | | ||
| + | |- | ||
| + | | | ||
| + | | Abbott | ||
| + | | | ||
| + | | | ||
| + | | align="center" | x | ||
| | | | ||
|- | |- | ||
Versie op 28 mei 2010 18:08
| Naam | Firma |
Consultatie/ advisering |
Wetenschappelijk onderzoek |
Congres/ andere reis | Cursus |
| Kees Brinkman | Viiv | x | x | x | |
| BMS | x | ||||
| MSD | x | x | |||
| Gilead | x | x | x | ||
| Roche | x | ||||
| Abbott | x | x | |||
| Jansen-Tibotec | x | x | x | ||
| Mariska Tuut | Geen | ||||
| Suzanne Geerlings | MSD | x | x | ||
| GSK | x | ||||
| BMS | x | x | |||
| Gilead | x | x | |||
| Abbott | x | x | |||
| Jansen Cilag (Tibotec) | x | ||||
| Pfizer | x | ||||
| Jet Gisolf | Roche | x | |||
| Merck | x | ||||
| Gilead | x | ||||
| Shering Plough | x | ||||
| Abbott | x | ||||
| Gerrit Schreij | Viiv Healthcare | x | x | ||
| Gilead | x | ||||
| Tibotec | x | ||||
| Roche | x | ||||
| MSD | x | ||||